However, the data from these studies provided high level evidence to support their use in clinic: The MINDACT (Microarray in Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy) clinical trial showed excellent 5-year distant metastasis-free (DMFS) survival of 94.7% (95% CI 92.5–96.2) in early-stage BC patients with high-clinical risk and low-genomic risk—assessed by MammaPrint test—who did not receive CT, confirming this patient population could be safely spared from adjuvant CT regardless of their nodal status, hormone-receptor, and HER2 expression. This evidence concerns the gene ERBB2 and breast cancer.